Information Provided By:
Fly News Breaks for January 8, 2019
BSX
Jan 8, 2019 | 09:53 EDT
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $40 price target on Boston Scientific after the company reported preliminary Q4 revenue at the high end of previously issued guidance of $2.525B-$2565B. In a research note to investors, O'Brien says he is "encouraged" after the preliminary Q4 and sees the stock up "a bit" today, adding that the company's quarter was "solid" with trends moving int he right direction. He continues to see upside to numbers, which, along with a steady multiple, should push shares higher.
News For BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.